If left undetected or untreated for years or decades, cervical intraepithelial neoplasia may progress to cervical cancer. Persistent human papillomavirus (HPV) infection is a necessary cause of cervical cancer. From 2000 to 2014, crude incidence rates of cervical cancer increased by 10% and 12.5% annually in urban and rural China, respectively. It is estimated that in 2015 cervical cancer caused 30,500 deaths and recorded 98,900 new cases. In China, cervical cancer is the second most common female malignancy and a leading cause of cancer-related death among women.
In 2018, there were approximately 570,000 new cases and 311,000 cervical cancer related deaths, more than 84% of which were from low- and middle-income countries (LMIC). The disease burden of cervical cancer has been substantial globally, especially for less developed regions. This does not alter our adherence to PLOS ONE policies on sharing data and materials. These funds were not related to this research.Ĭompeting interests: The authors have read the journal's policies and declare the following competing interests: HY received funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. In addition, HY received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. The specific roles of these authors are articulated in the ‘author contributions’ section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care. 16/137/109) using UK aid from the UK Government to support global health research and the Key Laboratory of Public Health Safety (Fudan University), Ministry of Education (grant number: GW2019-6). 81525023), National Institute for Health Research (NIHR) (grant no. IRB at Fudan Univeristy School of Public Health, E-mail: tel: +86-021- 54237051 130 Dong’an Rd., Shanghai, 200032, China.įunding: This research was supported by National Science Fund for Distinguished Young Scholars (No. Below is the contact information of the institutional review boards (IRB) that approved our study: IRB at Henan Cancer Hospital, E-mail: tel: +86-0371-65588251 127 Dongming Rd, Zhengzhou City, Henan Province, 450008, China.
Data sharing might be possible after the ethics committees examine the risks. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: The data are restricted due to the nature of the informed consent agreements and due to the presence of identifying patient information. Received: JanuAccepted: ApPublished: May 7, 2020Ĭopyright: © 2020 Wu et al. PLoS ONE 15(5):Įditor: Lei Gao, Chinese Academy of Medical Sciences and Peking Union Medical College, CHINA
#CHINABASED KEEP LINKDOC US SERIES#
(2020) The economic burden of cervical cancer from diagnosis to one year after final discharge in Henan Province, China: A retrospective case series study. Citation: Wu Q, Jia M, Chen H, Zhang S, Liu Y, Prem K, et al.
0 kommentar(er)
